In particular, the number of cases overexpressing p16Ink4A even in a submodal proportion of tumor cells, progressively increased from lower- to higher-grade neuroendocrine lung tumors, with percentages varying from 14.9% in TC to 100% in SCLC. This evidence concerns the gene CDKN2A and small cell lung carcinoma.